ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
4,967.23
-0.88%
US Tech 100
16,554.00
-2.26%
Dow Jones
37,986.40
0.56%
Brent Oil
86.625
0.00%
Bitcoin
63,980.48
0.24%
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Allergy Therapeutics Plc (AGY) Quote

Allergy Therapeutics Plc

Allergy Therapeutics Plc (AGY)

Argosy Minerals Inc
2.65
-0.20
(-7.02%)
Closed April 20 11:30AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.65
Bid
2.70
Ask
3.00
Volume
1,429,952
2.80 Day's Range 2.85
0.85 52 Week Range 3.80
Market Cap
135.844M
Previous Close
2.85
Open
2.85
Last Trade
733
@
2.7
(O)
Last Trade Time
Financial Volume
37,894p
VWAP
2.65
Average Volume (3m)
726,152
Shares Outstanding
4,766,439,938
Dividend Yield
-
PE Ratio
-3.17
Earnings Per Share (EPS)
-0.01
Revenue
59.59M
Net Profit
-43.07M

About Allergy Therapeutics Plc

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.allergytherapeutics.com
Headquarters
West Sussex, Gbr
Founded
1970
Allergy Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 2.85p. Over the last year, Allergy Therapeutics shares have traded in a share price range of 0.85p to 3.80p.

Allergy Therapeutics currently has 4,766,439,938 shares outstanding. The market capitalization of Allergy Therapeutics is £135.84 million. Allergy Therapeutics has a price to earnings ratio (PE ratio) of -3.17.

AGY Latest News

More News

Allergy Therapeutics PLC Director Resignation

Allergy Therapeutics PLC 03 April 2024           Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group")   Director Resignation   03 April 2024 Allergy Therapeutics (AIM: AGY), the...

April 03 2024
RNS Regulatory News

EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line

The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not s ...

March 27 2024
Alliance News

Allergy Therapeutics PLC Update on funding

Allergy Therapeutics PLC 27 March 2024     Allergy Therapeutics plc ("Allergy Therapeutics", the "Group" or "Company")   Update on funding   27 March 2024 Allergy Therapeutics plc (AIM: AGY...

March 27 2024
RNS Regulatory News

Allergy Therapeutics PLC Interim Results for six months ended 31 Dec 2023

Allergy Therapeutics PLC 27 March 2024     Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company" or the "Group")   Interim Results for the six months ended 31 December 2023  ...

March 27 2024
RNS Regulatory News

Allergy Therapeutics starts dosing patients in peanut allergy trial

Allergy Therapeutics PLC on Tuesday said it has commenced subcutaneous dosing of peanut allergic patients in its phas ...

March 12 2024
Alliance News

Allergy Therapeutics PLC VLP Peanut PROTECT Trial Update

Allergy Therapeutics PLC 12 March 2024       Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group")     Allergy Therapeutics commences subcutaneous dosing in peanut allergic...

March 12 2024
RNS Regulatory News

Allergy Therapeutics PLC VLP Peanut PROTECT Trial Update

Allergy Therapeutics PLC 12 March 2024       Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group")     Allergy Therapeutics commences subcutaneous dosing in peanut allergic...

March 12 2024
RNS Non-Regulatory

Allergy Therapeutics PLC Appointment of Shaun Furlong to Board of Directors

Allergy Therapeutics PLC 11 March 2024     Allergy Therapeutics plc ("Allergy Therapeutics", the "Group" or "Company")     Appointment of Dr. Shaun Furlong to Board of Directors   11 March...

March 11 2024
RNS Regulatory News

Allergy Therapeutics PLC Result of AGM

Allergy Therapeutics PLC 08 March 2024       Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group")   Result of Annual General Meeting     8 March 2024 Allergy Therapeutics plc...

March 08 2024
RNS Regulatory News

Allergy Therapeutics forecasts revenue drop but trials going well

Allergy Therapeutics PLC on Wednesday said revenue decreased in its latest half year, and expects to require further ...

February 14 2024
Alliance News
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2-7.017543859652.852.852.83022512.85DE
4-0.1-3.636363636362.753.022.75043252.8632056DE
120.312.76595744682.353.021.887261522.59352205DE
261.35103.8461538461.33.021.27511847762.12808805DE
52-0.6-18.46153846153.253.80.8513116911.87184711DE
156-20.6-88.602150537623.25400.855401608.2572682DE
260-7-72.53886010369.65400.8593111610.61222418DE

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TWGTop Wealth Group Holding Ltd
$ 3.73
(101.62%)
36.52M
CSLRComplete Solaria Inc
$ 0.465319
(75.59%)
16.64M
SHOTWSafety Shot Inc
$ 0.48
(60.00%)
6.71k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
MNDRMobile health Network Solutions
$ 27.2386
(33.72%)
10.35M
YYAIConnexa Sports Technologies Inc
$ 0.8943
(-57.21%)
13.4M
SBFMSunshine Biopharma Inc
$ 1.77
(-46.69%)
11.9M
GTIGraphjet Technology
$ 6.43
(-33.09%)
95.33k
ISPCiSpecimen Inc
$ 0.2883
(-31.52%)
2.86M
BGLCBioNexus Gene Lab Corporation
$ 0.5998
(-29.32%)
735.88k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
SQQQProShares UltraPro Short QQQ
$ 12.84
(6.38%)
219.91M
AGBAAGBA Group Holding Ltd
$ 1.255
(21.84%)
128.79M
TQQQProShares UltraPro QQQ
$ 49.48
(-6.20%)
125.4M
SINTSiNtx Technologies Inc
$ 0.0414
(3.50%)
109.94M

Discussion

View Full Feed
$27 $27 5 minutes ago
Imagine how many have that same feeling about borrowing. Perfectly designed plan to cull people and increase their lion's share.
COOP
DMC8 DMC8 5 minutes ago
My bad a typo, should be May 01, 2024.*
AMRN
janice shell janice shell 7 minutes ago
Me too. 'night!
Dodger1 Dodger1 7 minutes ago
Of Monsters to Children to Men to psychology

and AI Wow..Nice...but Remember Family, Hah...no family...no Love no Play...get it! I will open now..tell me what you want? Our souls our lives.

And how do you think you have control over that?
Does that mea
AABB
janice shell janice shell 12 minutes ago
Oh dear!
fuagf fuagf 13 minutes ago
Yep, open faced works without the bottom denture pretty well too. Another small nuisance is that the chewing is not as deliciously pleasingly easy either as have to be careful not to gouge the bottom gum too hard with the 3-4 far left upper teeth still left there. Not sure but i think one of them fe
Risk vs Reward Risk vs Reward 13 minutes ago
Down on 25 mil shares traded is waaaay worse than being down on 250 million shares traded.
ABQQ
doc063 doc063 14 minutes ago
HOPEFULLY BY NEXT WEEKEND. JMHO.
BTCUSD
janice shell janice shell 14 minutes ago
Yes. Cheesesteaks are divine!
Risk vs Reward Risk vs Reward 15 minutes ago
Devil’s advocate here…. Anyone tell me where this trades at by next Friday ?

Come on here’s your chance to shine instead of just spouting emotional nonsense about your little investment ( complete roulette game )

Please give reasons for share price proclamations if yo
ABQQ
janice shell janice shell 15 minutes ago
Kenji flattens the bread a bit to avoid that.
fuagf fuagf 16 minutes ago
Mouthwatering now .. https://www.google.com/search?client=firefox-b-d&q=Philly+Cheesesteak .
fuagf fuagf 17 minutes ago
Those tend to be a bit doughy for me sometimes.
janice shell janice shell 19 minutes ago
You can always make them open-faced. That way, they're also less fattening.
Risk vs Reward Risk vs Reward 19 minutes ago
So now we have comedians on board ? Is that your way of saying it’s not going to No Bid/.0001 ?

Or do you just need some help understanding life ?
ABQQ
fuagf fuagf 21 minutes ago
Ok, when i get a fortnight without doing too much on the pokies i will buy some good ham and salamis. And that special cave-like bread, which costs about twice the ordinary wholemeal loaves i go through. It is tastier though. Love it. Because of my lousy bottom denture a better way for me to eat all
dinogreeves dinogreeves 23 minutes ago
He already sold last few days, all out.
TGLO
janice shell janice shell 25 minutes ago
Or perhaps...

The Best French Bread Pizza Recipe
Classic French bread pizza upgraded with a heavy dose of garlicky butter, two cheeses, and fresh herbs.

https://investorshub.advfn.com/uimage/uploads/2024/4/20/ytrnximage.jpeg

https://www.seriouseats
carlson carlson 27 minutes ago
Yeah but it's written in disappearing ink!!!!!
ABQQ
janice shell janice shell 28 minutes ago
Yes. Burgers are burgers. Not a sandwich. The BLT should have won. Or the Philly Cheesesteak.
fuagf fuagf 29 minutes ago
Oh saw that earlier. LOL You guys played it well. The hamburger (beef is a vegetable,
lol, those wonderful little children) winner i remember was an unpopular choice here.
janice shell janice shell 29 minutes ago
Or not, once they're grown up. They may just crave French Bread Pizza...

The Best French Bread Pizza Recipe
Classic French bread pizza upgraded with a heavy dose of garlicky butter, two cheeses, and fresh herbs.

https://investorshub.advfn.com/uimage/uploads/2024/
fuagf fuagf 32 minutes ago
Yep, the point that those children may likely be more open to climate
change action than too many adults today are was a good one too.

Your Recent History

LSE
AGY
Allergy Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved